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Seasonal and pandemic strains of influenza have widespread implications for the global
economy and global health. This has been highlighted recently as the epidemiologic char-
acteristics for hospitalization and mortality for pandemic influenza H1N1 2009 are now
emerging. While treatment with neuraminidase inhibitors are effective for seasonal and pan-
demic influenza, prevention of morbidity and mortality through effective vaccines requires a
rigorous process of research and development. Vulnerable populations such as older adults
(i.e., > age 65 years) suffer the greatest impact from seasonal influenza yet do not have a
consistent seroprotective response to seasonal influenza vaccines due to a combination of
factors. This short narrative review will highlight the emerging epidemiologic characteristics
of pandemic H1N1 2009 and focus on immunosenescence, innate immune system re-
sponses to influenza virus infection and vaccination, and influenza vaccine responsiveness
as it relates to seasonal and H1N1 pandemic influenza vaccines.
PANDEMIC INFLUENZA H1N1 2009:
ORIGINS, EPIDEMIOLOGY, AND
TREATMENT OPTIONS
Influenza A is a single-stranded nega-
tive sense RNA virus that encodes eight
major genes, including two major surface
antigens: hemagglutinin (HA†) (16 sub-
types) and neuraminidase (NA) (nine sub-
types). The natural host of influenza A is
wild waterfowl, although domesticated
poultry and swine also can become infected
(creating potential for genetic reassortment
of strains from avian and swine origins).
Seasonal influenza poses a major global
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when potential strains create pandemics
through point mutations in genes encoding
HAandNA(antigenicdrift)orviralgenomic
reassortment of subtypes (especially during
interspecies transmission), often resulting in
the introduction of novel influenza strains
into the human population (antigenic shift).
The highly pathogenic “Spanish” influenza
was an avian-like H1N1 virus, and H1N1
virusesweredominantinhumanpopulations
from 1918 until approximately 1956. In
1957, reassortment of H1N1 with avian in-
fluenza strains resulted in the formation of a
newhumanpandemic,H2N2“Asian”strain.
In 1968, antigenic shift resulted in the ap-
pearanceofapandemicH3N2“HongKong”
strain. H1N1 strains reemerged beginning in
1976, when a novel strain causing an in-
fluenza outbreak among military personnel
at Fort Dix, New Jersey, was reported. This
strain did not spread beyond the military
base, but concern about a possible pandemic
led to a mass vaccination campaign in the
United States that resulted in more deaths
from vaccine-associated Guillain-Barre syn-
drome than had occurred from the Fort Dix
H1N1 strain. In 1977, a H1N1 strain nearly
identical to a strain circulating in the 1950s
reemerged in the former Soviet Union and
China. Such genetic preservation in the
known animal reservoirs for influenza virus
is conceivablebut wouldbe unexpected, and
there remains speculation that the 1977
Eurasian outbreak was the result of a labora-
tory accident in the region. Human H3N2
andH1N1strainshaveremainedinco-circu-
lationas seasonalinfluenzauntiltoday[1,2].
Less common strains with pandemic poten-
tial include avian H5N1 influenza. These
strains arehighly pathogenic inhumans with
inpatient mortality reported as ranging from
24 percent to 100 percent(the widerangere-
flecting the heterogeneity in affected age
groups and viral clades) [3]. Cases usually
reflect close exposure to poultry outbreaks
(with sick or dead animals) or, in rare cases,
are associated with person-to-person trans-
mission[3].Fortunately,atpresent,sustained
human-to-human transmission of H5N1
strains has not occurred [2,3].
Until recently, H5N1 avian strains of in-
fluenza were the predominant focus for sur-
veillance of potential new pandemic viral
strains. This obviously changed with the
emergence of the swine-related H1N1 strain
currently circulating in the United States and
around the world. It is noteworthy that oc-
casional transmission of swine-related
H1N1 strains to humans, usually in the set-
ting of exposure to pigs, has been reported
for decades and results in clinical presenta-
tions reminiscent of those being observed in
the current pandemic [4]. These earlier
swine-origin viruses are the result of a so-
called triple re-assortment, with five of the
eight influenza virus gene segments of
NorthAmerican swine lineage, two of North
American avian lineage, and one from the
human H3N2 influenzaAstrain. In the cur-
rent human pandemic H1N1 2009 strain,
two of the North American swine origin
gene segments (encoding the NAand M pro-
teins) have been replaced with segments
originating from Eurasian swine.The origin
of this novel re-assortment from four differ-
ent sources remains incompletely under-
stood at present [2,5,6].
Epidemiologiccharacteristicsofpatients
infected with pandemic H1N1 2009 have
begun to emerge from around the globe. In
general, both uncomplicated and critically ill
presentationsaresimilartothosereportedfor
seasonal influenza. However, in contrast to
seasonalinfluenza,inwhich90percentofthe
30,000to40,000annualdeathsareassociated
with individuals over age 65, early data indi-
cates increased mortality primarily in
younger individuals 20 to 49 years of age, as
well as patients with risk factors such as im-
munosuppression, pregnancy, or obesity [7-
9]. Possible explanations for the increased
burdenofdiseaseinyoungcomparedtoolder
adults(incontrasttoseasonalinfluenza)may
be the presence of preexisting cross-protec-
tive antibodies against the current pandemic
H1N1 2009 strain found in individuals over
theageof59.Thispresumablyreflectsexpo-
sureearlierinlifetorelatedH1N1strainscir-
culating in the 1950s [10,11].
Murine models lack some of the clinical
symptoms described above, but in cases of
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influenza-related pneumonia, they mirror
many of the changes found in the lower res-
piratory tracts of humans: vessel throm-
boses, necrosis and inflammatory infiltrates,
formation of hyaline membranes, hemor-
rhage, and alveolar damage [12]. Early evi-
dence with swine origin H1N1 influenza
virus strains has demonstrated high viral
titers in lower respiratory tract tissue leading
to an increased propensity to cause pneumo-
nia. This has been accompanied by an in-
crease in pro-inflammatory cytokines and
inflammatory infiltrate on histological ex-
amination [13,14]. Some of these findings
have been replicated in macaques and ferrets
[13-15]. Notably, in swine origin H1N1 in-
fluenza virus-related pneumonia, there are
some similarities in the aforementioned
pathological changes within lung tissue to
influenza H5N1-associated pneumonia
[2,16].
Assuggestedbytheworkinanimalmod-
els,thenovelpandemicH1N12009strainhas
resultedincomplicatedpresentationsrequiring
hospitalization. In a recent study reporting on
272 patients in the United States hospitalized
with pandemic H1N1 influenza, 25 percent
wereadmittedtotheICU[17].Amongpatients
presenting to the ICU, the mean Apache II
score was 20, mean age 29-44 years, and fe-
malesexpredominated.Majorco-morbidities
among critically ill patients in the United
States, Canada, and Mexico included chronic
lung disease, obesity, hypertension, diabetes,
and a smoking history [8,9,17]. The average
timetosymptomonsetwasthreetofourdays,
with common symptoms including fever, res-
piratory symptoms, weakness, myalgias,
headache, nausea, vomiting, or diarrhea
[8,9,17]. Common radiographic presentations
inthecriticallyillwerebilateralinfiltratesand
acute lung injury [9,17]. The 28- and 60-day
mortality among critically ill patients was 14
percent and 41 percent, respectively [8,9].
Thus, while this new strain of pandemic in-
fluenza results in uneventful recovery for the
vast majority of affected individuals, patients
requiring hospitalization are at increased risk
for morbidity and mortality.
Currently available antiviral therapy
against influenza targets either the influenza
M2 protein (adamantanes) or neuraminidase
(neuraminidase inhibitors). Neuraminidase
inhibitors in particular interfere with viral
neuraminidase-mediated cleavage of host
sialic-acid receptor residues, a critical step
in the release of newly created influenza vi-
rons from infected cells. The overwhelming
majority of pandemic H1N1 2009 strains are
susceptible to neuraminidase inhibitors such
as oseltamivir or zanamivir and resistant to
the adamantanes [18]. This contrasts with
seasonal influenza, in which circulating
H1N1 strains (A/Brisbane/59/2007) from
the 2008-2009 influenza season were found
to be uniformly resistant to oseltamivir [19].
In very rare cases, resistance to oseltamivir
in the pandemic H1N1 strain may arise
through a histidine to tyrosine substitution
in the active site of neuraminidase (H275Y);
additionally, a novel viral mutation found in
close contacts receiving oseltamivir also has
been reported (I223V) [20]. However, the
clinical significance of oseltamivir resist-
ance for pandemic H1N1 influenza remains
unclear [21]. In severe hospitalized adult or
pediatric patients with suspected or labora-
tory confirmed pandemic H1N1 2009 strains
or infections suspected to be pandemic
H1N1 2009 based on community epidemi-
ology, peramivir (an intravenous formula-
tion of a neuraminidase inhibitor currently
entering phase III clinical studies) may be
available via Emergency UseAuthorization
from the U.S. Food and Drug Administra-
tion (FDA) for individuals unable to take os-
eltamavir (which can only be administered
by mouth) or zanamavir (which can only be
given in inhaled form) [22]. Available data
on peramivir suggest a prolonged half-life
in humans and peak plasma concentrations
that are two-fold higher than oral os-
eltamivir; however, clinical data on efficacy
are still lacking [23]. Peramivir should not
be used in cases of documented or suspected
oseltamivir resistance.
VACCINE DEVELOPMENT
The widespread implications of pan-
demic H1N1 2009 influenza necessitated the
development of an effective vaccine. Epi-Joshi: Pandemic influenza H1N1 2009 146
demic models projected savings in excess of
$300 million and prevention of 1,468 deaths
if 40 percent of the population in a large
U.S. city were vaccinated against pandemic
influenza during November [24]. Based
upon antigen similarities among circulating
strains, the World Health Organization
(WHO) and FDA recommended a monova-
lent H1N1 vaccine strain using influenza
A/California/7/2009 [25,26]. The pandemic
H1N1 vaccine was produced in a manner
similar to seasonal influenza vaccine, under-
went the same licensing standards in the
United States, and is currently available
without adjuvant in either a monovalent live
attenuated formulation administered in-
tranasally or in an inactivated formulation
for intramuscular injection [25].The live at-
tenuated formulation is a cold adapted virus
that optimally grows at lower temperatures
in the nasal mucosa and cannot replicate at
core body temperatures. In doing so, replica-
tion of the attenuated virus in the upper res-
piratory tract elicits a systemic and local
mucosal immune response. While this tech-
nology has been safely employed for in-
fluenza immunization since 2003, this
formulation should not be administered to
certain subsets of the population, including
those: 1) younger than 2 or older than 50
years of age; 2) with immunosuppressive
conditions; 3) with chronic underlying med-
ical conditions; 4) who are pregnant; 5) with
a prior history of Guillain-Barre syndrome;
6) with severe egg allergy; or 7)
children/adolescents receiving aspirin ther-
apy. Preliminary evidence from a phase II
clinical trial enrolling healthy adults 18 to
64 years using an monovalent inactivated
pandemic H1N1 vaccine without adjuvant
demonstrated 96.7 percent of subjects had
HI titer > 1:40 and 70.8 percent patients se-
roconverted or had a significant increase in
antibody titer after one dose containing 15
ﾵg of HA [27]. Combined with data from
other FDA approved manufacturers of pan-
demic H1N1 vaccine, the immunologic re-
sponse has been similar to the historical
seasonal influenza vaccine efficacy rates of
70 percent to 90 percent in young healthy
adults [25]. Based upon experiences with
seasonal vaccine (see below), manufacturers
note the possibility of being unable to repli-
cate such robust immune responses using
the pandemic vaccine in immunocompro-
mised populations or older adults. Since
pathogen-associated molecular pattern
recognition by the innate immune system
guides the formation of the adaptive re-
sponse, it is important to understand the spe-
cific innate immune responses to influenza
vaccine and how can they be modified to
create more effective vaccine, particularly in
older adults. In this report, we will further
describe: i) immunosenescence and in-
fluenza vaccine efficacy/effectiveness and
ii) the innate immune response to seasonal
and pandemic H1N1 2009 influenza virus
vaccines.
IMMUNOSENESCENCE OF THE
ADAPTIVE AND INNATE IMMUNE
SYSTEM
It is generally accepted that the seasonal
influenza vaccine has decreased efficacy and
effectiveness in older adults compared to
younger patients. In combined analyses of
community dwelling older adults, seasonal
vaccines have an effectiveness ranging from
17 percent to 53 percent [28-30]. Biological
plausability arises from the multifactorial
combination of antigenic match of vaccine
and virus, nutritional status, frailty, co-mor-
bid conditions, and immunosenescence of
the adaptive and innate immune systems
[31]. Broadly, the adaptive immune system
protects the host through antigen specific re-
sponses and the development of immuno-
logic memory. Changes in the adaptive
immune system with aging include de-
creased numbers of na￯ve B and T cells,
oligoclonality of T and B cell receptors and
reduced signaling, decreased replicative
ability of T cells, and decreased im-
munoglobulin class switching capability of
B cells [32-34].
The earliest immunologic responses to
seasonal and non-seasonal influenza A
viruses are led by activation of the innate
immune system. In contrast to the adaptive
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the exceptional antigen specificity and im-
munologic memory associated with the
adaptive immune system. The innate im-
mune system is activated by germline en-
coded invariant pattern recognition receptors
(PRR) that recognize cellular damage or a
broad array of pathogens by recognizing
unique conserved sequences known as
Pathogen-Associated Molecular Patterns
(PAMP); important examples of PRR in-
clude Toll-Like Receptors (TLR), Nu-
cleotide-binding domain and
Leucine-rich-repeat Receptors (NLR), and
Retinoic acid-inducible gene-I Like Recep-
tors (RLR).Toll-like receptors are one of the
key components of the innate immune sys-
tem and are found primarily in antigen pre-
senting cells within the cell membrane or
endosome.TLRs are important in triggering
the host response against PAMP from gram
positive and negative bacteria, mycobacte-
ria, and viruses, including lipopeptides and
lipoproteins, lipoteichoic acid, unmethylated
nucleic acid sequences, lipopolysaccharide,
and flagellin. Activation of TLRs result in
proinflammatory signaling and is an impor-
tant link in forming the adaptive immune re-
sponse. TLR7 is an important endosomal
PRR for the ssRNA of influenza virus [35-
37]. Once TLR7 recognizes ssRNA, the
adaptor protein myeloid differentiation pri-
mary response protein 88 (MyD88), via
down-stream signal activation of transcrip-
tion factors, results in the production of type
I Interferons (IFNs) and inhibition of viral
replication.
Among several cytoplasmic PRR, the
NLR family member NLRP3 is involved in
recognizing molecules such as alum or viral
nucleic acid [38-42]. Upon sensing these lig-
ands, protein interactions among domains of
NLRs, the adaptor protein ASC, and Cas-
pase-1 (a cysteine protease) ultimately form
the multi-protein inflammasome structure.
The inflammasome is responsible for cleav-
ing immature forms of proinflammatory cy-
tokines in a caspase-1 dependent manner to
their mature forms protecting the host
against a viral infection. Another group of
cytoplasmic PRR are the RLR, which in-
clude RNAhelicases such as RIG-I that rec-
ognize 5’ triphosphate ssRNA and dsRNA.
After infection with influenza A in human
macrophages, reorganization of the actin
and tubulin skeleton brings RIG-I in prox-
imity to its adaptor molecule Mitochondrial
Antiviral Signaling Protein (MAVS). This
interaction leads to downstream activation
of several nuclear transcription factors ulti-
mately resulting in type I IFN production
and the host’s antiviral response [43].
In addition to the adaptive immune sys-
tem, concomitant dysregulation of the innate
immune system with aging plays a major
role in the response to influenza vaccine and
infection in older adults in several ways, in-
cluding: 1) altered expression, regulation,
and function of PRR and costimulatory mol-
ecules; 2) altered secretion of inflammatory
chemokines, cytokines, and anti-microbial
peptides; and 3) decreased function of NK
cells, macrophages, and neutrophils [31,32].
Since the innate immune system is linked to
subsequent development of adaptive immu-
nity, the combination of these innate defects
can lead to reduced adaptive immune re-
sponses against a viral pathogen [31,44,45].
There are important age-related defects
in several TLR and co-stimulatory mole-
cules that have an impact on a host’s re-
sponse to bacterial or viral PAMP. During
the course of an influenza infection, bacter-
ial super-infection may play a major role in
morbidity/mortality [9,17]. For example,
over a four-month period, 29 percent of 77
post-mortem lung samples from confirmed
cases of pandemic H1N1 2009 demonstrated
evidence of coexistent bacterial infection
[46]. In animal models, bacterial PAMP,
such as lipopolysaccharide (aTLR4 ligand),
have been used to stimulate macrophages in
older mice; the results have shown de-
creased expression of proinflammatory cy-
tokines: TNF-α and IL-6 [47]. Stimulation
of TLR1/2 (which recognize triacylated
lipopeptides) in monocytes from older
adults yielded a blunted production ofTNF-
α and IL-6; additionally, TLR1 had de-
creased surface expression [48]. In normal
immunologic responses, TLR activation of
monocytes and DCs results in activation of
costimulatory molecules CD80 and CD86.Joshi: Pandemic influenza H1N1 2009 148
In older adults however, there has been age-
related altered expression of these costimu-
latory molecules that subsequently predicted
a seroprotective response to influenza vac-
cine [49]. More recent studies have indi-
cated more extensive defects in TLR
function in specific classes of human den-
dritic cells from older individuals compared
to young individuals that are predictive of
antibody response to influenza immuniza-
tion [50]. Whether there are any age-related
defects in NLR and RLR function remains
poorly understood; however, the available
evidence indicates that alterations in innate
immune function have major implications in
the response of older adults to seasonal in-
fluenza vaccine and related bacterial infec-
tions.
INNATE IMMUNE RESPONSE TO
ADJUVANT
Adjuvants are compounds co-adminis-
tered with antigens that alter the physical de-
livery of antigens or improve the biological
activity against the antigen.This clinical ap-
plication enhances the immunoprotectivere-
sponse (both potency and duration) in
populations with traditionally poor re-
sponses to vaccines — such as older adults.
A significant proportion of the initial re-
sponse to vaccine adjuvants is facilitated by
components of the innate immune system.
Although currently not used in U.S.-based
formulations of any influenza virus vaccine,
adjuvants such as MF59 (a proprietary oil in
water emulsion), CpG (a known TLR9 lig-
and), or alum into muscle results in local in-
filtration of antigen presenting cells,
proinflammatory cytokines, and chemokines
[51]. Of note, MF59 adjuvanted vaccines are
currently used in Europe. Alum has been
shown to recruit cells important in the innate
immune response and assist in T cell prim-
ing [52]. The innate immune system’s re-
sponse to adjuvant is important in directing
the formation of the adaptive immune re-
sponse. Similar to MF59, the use of alum
adjuvanted antigens resulted in improved
antigen presentation from monocytes,
myeloid DC (mDC), and plasmacytoid DC
(pDC) via improved antigen uptake. Addi-
tionally, adjuvant increased the expression
of costimulatory markers and the differenti-
ation of monocytes into dendritic cells. The
combination of these changes in the innate
immune system led to more robust adaptive
immune responses as measured by proin-
flammatory cytokines and rate of T cell
clonal expansion [53].
Clinical implications of the use of adju-
vant recognition by the innate immune sys-
tem have been improved adaptive immunity
in humans immunized with influenza vac-
cine. The H5N1 pre-pandemic strain with
the adjuvant MF59 had a more robust adap-
tive immunologic response compared to
non-adjuvanted version in preclinical trials
[54]. The application of adjuvants has had
preliminary evidence of a tolerable safety
profile for both pandemic and seasonal in-
fluenza vaccines [55-57]. Results from a
phase 1 clinical trial of inactivated monova-
lent pandemic H1N1 2009 vaccine with or
without MF-59 demonstrated an improved
seroprotective response within two weeks of
a single dose of adjuvanted 7.5 ﾵg of HA;
the geometric mean titers of adjuvanted vac-
cine were similar at half the standard in-
fluenza dose and at an earlier point in time
compared to an unadjuvanted inactivated
pandemic H1N1 2009 monovalent vaccine
[27,55]. Interestingly, a pandemic H1N1
2009 inactivated strain adjuvanted with
alum did not enhance the immunogenicity
as MF-59 appears to be a more potent in-
ducer of the innate immune system com-
pared to alum [57]. These clinical trials
highlight the importance of further studying
adjuvanted formulations of influenza vac-
cine, especially in populations (i.e., older
adults) who classically have reduced im-
munologic responses to vaccines (as dis-
cussed above).
CONCLUSIONS AND OUTLOOK
Approaches aimed at improving the im-
munogenic response to seasonal influenza
vaccine in older adults range from higher
doses containing 60 ﾵg of HA in the inacti-
vated vaccine to creating vaccines directedJoshi: Pandemic influenza H1N1 2009 149
against universal influenza antigens, recom-
binant trivalent HAantigen alone, DNAvac-
cines encoding HA, or the development of
monoclonal antibodies against highly con-
served regions of HAamong many influenza
strains [58-61]. Since the use of adjuvants in
seasonal influenza vaccine improves im-
munogenicity (especially in vulnerable pop-
ulations like older adults) through
interactions with the innate immune system,
future areas of research should concentrate
on developing new classes of vaccine adju-
vant to improve host protection [62].
The typical seasonal influenza burden
on the health care system and global econ-
omy have become magnified with the rapid
transmission of the pandemic H1N1 2009
strain. Increased mortality in younger pa-
tients necessitated the need for an effective
vaccine. By translating knowledge of innate
immunobiologic responses against vaccines,
future strategies will develop more effective
vaccines against influenza.
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